Acute Lymphoblastic Leukemia in Adults

The prognosis of patients with acute lymphoblastic leukemia is constantly improving. Beside optimization strategies of conventional chemotherapies and close monitoring of treatment response (e.g. by PCR-based measurement of measurable disease, which helps to early identify patients at risk for relapse), the integration of antibody (e.g. anti-CD20)/antibody-based drugs (blinatumomab and inotuzumab-ozogamicin) to frontline and/or salvage therapy protocols led to significant improvements. However, allogeneic HCT still plays a fundamental role in the treatment of high-risk patients in 1st line consolidation and for patients with relapsed/refractory disease.